A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer

NCT02826161 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

4

Enrollment

INDUSTRY

Sponsor class

Stopped Change of treatment landscape and evolving standard of care

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: Napabucasin
DRUG: Paclitaxel

Sponsor

Sumitomo Pharma America, Inc.